CA-HURRICANE-ELECTRIC
24.5.2022 11:22:03 CEST | Business Wire | Press release
Hurricane Electric , the world’s largest IPv6-native Internet backbone announced today that it has further expanded its presence in Southeastern Europe by connecting to the Albanian Neutral Internet eXchange (ANIX).
ANIX is the first neutral and not-for-profit Internet Exchange point in Albania and is hosted and managed by Namex in the carrier-grade data center of RASH , the Albanian Academic Network, in Tirana. ANIX went live in March 2018. Prior to the establishment of ANIX, traffic between Albanian endpoints had to pass through foreign countries. ISPs throughout Albania and the world come to ANIX to interconnect their networks.
Hurricane Electric’s presence in ANIX will provide reduced latency and improved fault tolerance, load balancing and congestion management infrastructure. The added direct connectivity paths also increase the reach of Hurricane Electric’s next-generation (IPv6) Internet infrastructure and services. Additionally, ANIX members can now exchange IP traffic, or “peer,” with Hurricane Electric’s rich global Internet backbone.
Namex is an Internet Exchange Point based in Rome, Italy, established in 1995. Namex and RASH, the Albanian Academic Network, established in 2007, have been conducting the ANIX pro-bono effort to improve the connectivity of Albanian ISPs to each other and to the global Internet. ANIX features state-of-the-art devices, installed in the RASH data center which is equipped with numerous features to ensure uptime, including N + 1 UPS, temperature and humidity sensors, and real-time monitoring of the facility’s critical infrastructure.
In addition to providing increased network capacity through 100GE (100 Gigabit Ethernet), 10GE (10 Gigabit Ethernet) and GigE (1 Gigabit Ethernet) ports, Hurricane Electric’s vast global network, offers over 20,000 BGP sessions with over 9,000 different networks via more than 250 major exchange points and thousands of customers and private peering ports.
“Hurricane Electric’s is excited to connect to ANIX while expanding our footprint in Southeastern Europe," said Mike Leber, President of Hurricane Electric. “The new connection will enable local ISPs and other networks to take advantage of Hurricane Electric’s rich global network, while helping to strengthen Albania’s Internet connectivity.”
About Hurricane Electric
Hurricane Electric operates its own global IPv4 and IPv6 network and is considered the largest IPv6 backbone in the world. Within its global network, Hurricane Electric is connected to over 250 major exchange points and exchanges traffic directly with more than 9,000 different networks. Employing a resilient fiber-optic topology, Hurricane Electric has no less than five redundant 100G paths crossing North America, four separate 100G paths between the U.S. and Europe, and 100G rings in Europe and Asia. Hurricane also has a ring around Africa and a ring through Australia and New Zealand. Hurricane Electric offers IPv4 and IPv6 transit solutions over the same connection. Connection speeds available include 100GE (100 gigabits/second), 10GE, and gigabit ethernet. Additional information can be found at http://he.net .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523006059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
